Clinical Efficacy and Safety of Sarasvata Ghrita in the Management of Cognitive Deficit–A Prospective Open Label Study

JOURNAL TITLE: Journal of Research in Ayurvedic Sciences

Author
1. Chandra Shekhar Rao
2. Bhagwan Sharma
3. Hemant K Gupta
4. Srinibash Sahu
5. Guru Charan Bhuyan
ISSN
2456-5601
DOI
10.5005/jp-journals-10064-0041
Volume
2
Issue
2
Publishing Year
2018
Pages
7
Author Affiliations
    1. Central Council for Research in Ayurvedic Sciences, New Delhi
    1. Advanced Centre for Ayurveda in Mental Health and Neuro Sciences, Bengaluru
    1. Advanced Centre for Ayurveda in Mental Health and Neuro Sciences, Bengaluru
    1. Central Ayurveda Research Institute for Hepatobiliary Disorders, Bhubaneswar
    1. Sawai ManSingh Medical College, Jaipur, Rajasthan, India
  • Article keywords
    Budhimandyta, Cognitive deficit, Sarasvata Ghrita

    Abstract

    Introduction: Cognitive deficit describes deficit in global intellectual performances. It is a condition which usually begins in childhood, and the patient shows significant limitations in their ability to learn and function. Its cause may be congenital or may occur due to environmental factors such as brain injuries, neurological disorders, or mental illness, etc. The cognitive deficit can be correlated with Budhimandyata in Ayurveda. Objective: To evaluate the efficacy and safety of Sarasvata Ghrita in the patients suffering from cognitive deficit. Materials and methods: A prospective, open-label study was carried out at Advanced Center for Ayurveda in Mental Health and Neurosciences, Bengaluru (ACAMH and NS). Fortyfive cognitive deficit children satisfying the selection criteria were selected from the out patient department (OPD) of ACAMH and NS, NIMHANS, Bangalore, were administered Sarasvata Ghrita (6 gms) twice daily before food with lukewarm water for three months. Assessment parameters Intelligent Quotient (IQ) by Binet Kamat test (BKT), mini mental state examination (MMSE), abnormal behavior check (ABC) and parental perception evaluation were assessed at the baseline, on the 60th day and on the 90th day. Paired sample t-test was used to compare mean change from baseline to the 84th day. A p- value of <0.05 was considered significant. Results: At the end of the 90th Day, compared with baseline statistically, significant improvement was observed in BKT IQ score, MMMSE score, ABC list score and the parental perception score (p < 0.001). Hematological and biochemical laboratory parameters were also assessed before and after the trial (there was not any significant change in them). Conclusion: Sarasvata Ghrita taken internally by cognitive deficit children is helpful in improving their IQ, MMSE and ABC scores. It was also found safe as it does not produce any adverse event.

    © 2019 Jaypee Brothers Medical Publishers (P) LTD.   |   All Rights Reserved